LPI-labile plasma iron in iron overload

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 2 SPEC. ISS., 2005, Pages 277-287

  Cabantchik, Z Ioav ^a   Breuer, William ^a   Zanninelli, G ^b   Cianciulli, P ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b S EUGENIO HOSPITAL   (Italy)

Author keywords

Ascorbate; Fluorescence; Hemochromatosis; Hemosiderosis; High throughput assay; Iron overload; Labile plasma iron; Oxidative stress; Thalassemia; Transfusion

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEMOGLOBIN E; IRON; LABILE PLASMA IRON; TRANSFERRIN; UNCLASSIFIED DRUG;

BETA THALASSEMIA; BLOOD TRANSFUSION; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; ERYTHROCYTE MEMBRANE; FERRITIN BLOOD LEVEL; HEART FUNCTION; HEMOSIDEROSIS; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; REVIEW; SURVIVAL; THALASSEMIA MAJOR;

EID: 14544271816     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.10.003     Document Type: Review

References (36)

1. D.J. Weatherall Pathophysiology of thalassaemia Baillieres Clin Haematol 11 1998 127-146
2. J.P. Kushner J.P. Porter & N.F. Olivieri Secondary iron overload Hematology (Am Soc Hematol Educ Program) 2001 47-61
3. L. Merson & N. Olivieri Orally active iron chelators Blood Rev 16 2002 127-134
4. Z.D. Liu & R.C. Hider Design of clinically useful iron(III)-selective chelators Med Res Rev 22 2002 26-64
5. G.M. Brittenham S. Sheth C.J. Allen & D.E. Farrell Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease Semin Hematol 38 supplement 1 2001 37-56
6. A.V. Hoffbrand A. Cohen & C. Hershko Role of deferiprone in chelation therapy for transfusional iron overload Blood 102 2003 17-24
7. R. Fischer & R. Engelhardt Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility Lancet 361 2003 182-183
8. R. Fischer F. Longo P. Nielsen et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: Application of SQUID biomagnetic liver susceptometry Br J Haematol 121 2003 938-948
9. A. Piga C. Gaglioti E. Gogliacco & F. Tricta Comparative effects of defriprone and deferioxamine on survival and cardiac disease in thalasssemia major: A-retrospective study Hematologia 88 2003 489-496
10. M. Galia M. Midiri V. Bartolotta et al. Multicenter trial group of the society for the study of thalassemia and haemoglobinopathies. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study Hemoglobin. 27 2003 63-76
11. P.D. Jensen F.T. Jensen T. Christensen et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: Indication of close relation between myocardial iron content and chelatable iron pool Blood 101 2003 4632-4639
12. G.C. Ooi P.L. Khong G.C.F. Chan et al. Magnetic resonance screening of iron status in transfusion-dependent b-thalassaemia patients Br J Haematol 124 2004 385-390
13. N. Papanikolaou A. Ghiatas A. Kattamis et al. Non-invasive myocardial iron assessment in thalassaemic patients: T2 relaxometry and magnetization transfer ratio measurements Acta Radiol 41 2000 348-351
14. M. Westwood L.J. Anderson & D.J. Pennell Treatment of cardiac iron overload in thalassemia major Haematologica 88 2003 481-482
15. J.C. Wood J.M. Tyszka S. Carson et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease Blood 103 2004 1934-1936
16. L. Mancuso G. Panzarella T.V. Bartolotta et al. Cardiac complications in thalassemia: Noninvasive detection methods and new directions in the clinical management Expert Rev Cardiovasc Ther 1 2003 439-452
17. C. Hershko G. Graham G.W. Bates & E.A. Rachmilewitz Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity Br J Haematol 40 1978 255-263
18. W. Breuer C. Hershko & Z.I. Cabantchik The importance of non-transferrin bound iron in disorders of iron metabolism Transfus Sci 23 2000 185-192
19. I. Gosriwatana O. Loreal S. Lu et al. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin Anal Biochem 273 1999 212-220
20. J.B. Porter R.D. Abeysinghe L. Marshall et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy Blood 88 1996 705-710
21. W. Breuer & Z.I. Cabantchik A fluorescence-based one-step assay for serum non-transferrin-bound iron Anal Biochem 299 2001 194-202
22. B.P. Esposito W. Breuer P. Sirankapracha et al. Labile plasma iron in iron overload: Redox activity and susceptibility to chelation Blood 102 2003 2670-2677
23. P. Pootrakul W. Breuer M. Sametband et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded beta-thalassaemia/HbE patients treated with an oral chelator Blood 104 2004 1504-1510
24. P.J. Giardina & R.W. Grady Chelation therapy in beta-thalassemia: An optimistic update Semin Hematol 38 2001 360-366
25. B. Modell M. Khan & M. Darlison Survival in betathalassaemia major in the UK: Data from the UK Thalassaemia Register Lancet 355 2000 2051-2052
26. N.F. Olivieri D.G. Nathan J.H. MacMillan et al. Survival in medically treated patients with homozygous beta-thalassemia N Engl J Med 331 1994 574-578
27. C. Hershko M.D. Cappellini R. Galanello et al. Purging iron from the heart Br J Haematol 125 2004 545-551
28. L.J. Anderson S. Holden B. Davis et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload Eur Heart J 22 2001 2171-2179
29. L.J. Anderson B. Wonke E. Prescott et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia Lancet 360 2002 516-520
30. H. Gunshin B. Mackenzie U.V. Berger et al. Cloning and characterization of a proton-coupled mammalian metal ion transporter Nature 388 1997 482-488
31. G.Y. Oudit H. Sun M.G. Trivieri et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy Nat Med 9 2003 1187-1194
32. B.A. Davis & J.B. Porter Results of long term iron chelation treatment with deferoxamine Adv Exp Med Biol 509 2002 91-125
33. C. Le Lan T. Cohen M. Ropert et al. Labile plasma iron in C282Y/C282Y hemochromatosis: A reality of potential pathophysiological and clinical importance Le Lan C, Cohen Hepatol 38 No. 4 supplement 1 2003 661A
34. W. Breuer M.J. Ermers P. Pootrakul et al. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy Blood 97 2001 792-798
35. M. Sulieman R. Asleh Z.I. Cabantchik et al. Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes mellitus Diabetes Care 27 2004 2730-2732
36. A. Winder Z.I. Cabantchik D. Merkel & E.A. Rachmilewitz Possible implications of measurable quantities of non transferrin bound iron (NTBI) in Myelodysplastic Syndrome Blood 102 11 2003 916a